As expected, the SCI/MCI group had less deviating CSF AD biomarker levels (Aβ1–42, P-tau, and T-tau) and lower presence of the APOEɛ4 allele compared with the AD group. The gene discussed is MAPT; the disease is Alzheimer disease.